Less than 1 min.Read

Mekonos: Raises $4.6M in Funding

December 6, 2020

Mekonos, a San Francisco, CA-based biotech company launching a system-on-a-chip (SoC) for targeted ex vivo gene engineering, completed a $4.6m financing round
The round was led by Novartis AG with participation from institutional VCs including Hike Ventures, CRCM Ventures
The company will also use the new capital to accelerate the SoC platform for its current and new commercial partnerships
Led by Anil Narasimha, Ph.D., Co-Founder and CEO, Mekonos is a biotech company advancing a gene engineering platform SoC platform, with IP from Stanford University
The platform also helps companies increase capacity, accelerate discoveries, and develop new pre-clinical assets in the emerging cell and gene therapy space
Mekonos recently completed pilots with key top pharmaceutical companies and research institutes that demonstrated high efficacy of modified gene expression and cell viability